Modification of tumor blood flow: Current status and future directions

Seminars in Radiation Oncology

Volumn 8, Issue 3, 1998, Pages 151-163

  Chaplin, D J ^a   Hill, S A ^a   Bell, K M ^a   Tozer, G M ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN; ANTINEOPLASTIC AGENT; CARBON DIOXIDE; COLCHICINE; COMBRETASTATIN A4; DIETHYLAMINE; DIMETHYLXANTHENONE ACETIC ACID; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; HYDRALAZINE; MITOFLAXONE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NICOTINAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; HYPERTHERMIC THERAPY; HYPOXIA; METASTASIS POTENTIAL; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0031926037     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(98)80041-6     Document Type: Article

References (121)

1. Jain RK Ward Hartley K Tumour blood flow—characterisation modifications and role in hyperthermia IEEE Trans Sonics Ultrasonics SU-31 1984 504 526
2. Jirtle RL Chemical modification of tumour blood flow Int J Hyperthermia 4 1988 355 371
3. Chaplin DJ The effect of therapy on tumour vascular function Int J Radiat Biol 60 1991 311 325
4. Chaplin DJ Trotter MJ Chemical modifiers of tumour blood flow Vaupel P Jain RK Tumour Blood Supply and Metabolic Microenvironment 1991 Gustav Fischer Verlag Stuttgart, Germany 65 85
5. Suzuki M Hori K Abe I A new approach of cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II J Natl Cancer Inst 69 1981 663 669
6. Burton MA Gray BN Self GW Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II Cancer Res 45 1985 5390 5393
7. Burton MA Gray BN Colletti A Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma Eur J Cancer Clin Oncol 21 1988 1373 1376
8. Ackerman NB Jacobs R Effects of epinephrine and other vasconstrictory agents on intraheptic tumour blood flow Tsuchiya M Microcirculation—an Update 1987 Elsevier Amsterdam, Netherlands 817 818
9. Trotter MJ Chaplin DJ Olive PL Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carinoma Eur J Cancer 27 1991 887 893
10. Tozer GM Shaffi KM Modification of tumour blood flow using the hypertensive agent, angiotensin II Br J Cancer 67 1993 981 988
11. Ekelund L Lunderquist A Pharmacoangiography with angiotensin Radiology 110 1974 533 540
12. Takematsu H Tomita Y Kato T Angiotensin induced hypertension and chemotherapy for multiple lesions of malignant melanoma Br J Dermatol 113 1985 463 485
13. Kuroiwa T Aoki K Hasuda K Efficacy of two-route chemotherapy using cis-diammine dichloroplatinum (II) and its antidote sodium thiosulphate in combination with angiotensin II in rat limb tumour Cancer Res 47 1987 3618 3623
14. Hori K Suzuki M Tanda S Fluctuations in tumour blood flow under normotension and the effect of angiotensin II-induced hypertension Jpn J Cancer Res 82 1991 1309 1316
15. Tanda S Hori K Saito S Comparison of the effects of intravenously bolus-administered endothelin-1 and infused angiotensin II on the subcutaneous tumour blood flow in anaesthetized rats Jpn Cancer Res 82 1991 958 963
16. Tokuda K Abe H Sugimoto S Modification of tumor blood flow and enhancement of therapeutic effect of ACNU on experimental rat gliomas with angiotensin II J Neurooncol 8 1990 205 212
17. Jirtle RL Chemical modification of tumour blood flow Int J Hyperthermia 4 1988 355 371
18. Tozer GM Shaffi KM Prise VE Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: Relationship to receptor distribution Int J Cancer 65 1996 658 663
19. Voorhees WD Babbs CF Hydralazine-enhanced selective heating of transmissable venereal tumour implants in dogs Eur J Cancer Clin Oncol 19 1982 1027 1033
20. Chaplin DJ Acker B The effect of hydralazine on the tumour cytotoxicity of the hypoxic cell cytotoxin RSU1069: Evidence for therapeutic gain Int J Radiat Oncol Biol Phys 13 1987 579 585
21. Brown JM Exploitation of bioreductive agents with vasoactive drugs Fielder EM Proceedings of the Eighth International Congress on Radiation Research Edinburgh, UK 1987 Taylor & Francis 719 724
22. Horsman MR Kent L Christensen MD Relationship between the hydralazine-induced changes in murine tumour blood supply and mouse blood pressure Int J Radiat Oncol Biol Phys 22 1992 455 458
23. Horsman MR Christensen KL Overgaard J Hydralazine-induced enhancement of hyperthermia damage in a C3H mammary carcinoma in vivo Int J Hyperthermia 5 1989 123 136
24. Chaplin DJ Hydralazine induced tumor hypoxia: A potential target for cancer chemotherapy J Natl Cancer Inst 81 1989 618 622
25. Stratford IJ Adams GE Godden J Potential of the anti-tumour effect of melphalan by the vasoactive agent hydralazine Br J Cancer 58 1988 122 127
26. Chaplin DJ Acker B Olive PL Potentiation of the tumour cytoxicity of melpalan by vasodilating drugs Int J Radiat Oncol Biol Phys 16 1989 1131 1135
27. Chaplin DJ Acker BD Horsman MR Reduction in tumour blood flow by vasoactive drugs: A role in cancer therapy Biomed Biochem Acta 48 1989 255 259
28. Siemann DW Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine Br J Cancer 62 1990 348 353
29. Rowell NP Flower MA McCready VR The effect of single dose oral hydralazine on blood flow through human lung tumours Radiol Oncol 18 1990 283 292
30. Dewhirst MW Madwed D Meyer RE Reduction in tumour blood flow in skin flap tumour after hydralazine is not due to a vascular steal phenomenon Radiat Oncol Invest 1 1994 270 278
31. Peterson HI Modification of tumour blood flow—a review J Radiat Biol 60 1991 201 210
32. Tozer GM Everett SA Nitric oxide in tumor biology and cancer therapy: Part I. Physiological aspects Clin Oncol 9 1997 282 293
33. Andrade SP Hart IP Piper PJ Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature Br J Pharmacol 107 1992 1092 1095
34. Wood P Stratford IJ Adams VE Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability Biochem Biophys Res Commun 192 1993 505 510
35. G-nitro-L-arginine Cancer Res 54 1994 6458 6463
36. Wood PJ Sansom JM Stratford IJ Modification of metabolism of transplantable and spontaneous murine tumours by the nitric oxide sythase inhibitor, nitro-L-arginine Int J Radiat Oncol Biol Phys 29 1994 443 447
37. Meyer RE Shan S DeAngelo J Nitric oxide synthase inhibition irreversibly decreases perfusion in the R323OAc rat mammary adenocarcinoma Br J Cancer 71 1995 1169 1174
38. Fukumura D Yuan R Endo M Role of nitric oxide in tumour microcirculation Am J Pathol 150 1997 713 725
39. (suppl) Horsman MR Chaplin DJ Hill SA Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours Br J Cancer 74 1996 S168 S171
40. Hahn JS Braun RD Dewhirst MW Stroma free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow oxygen partial pressure Radiat Res 147 1997 185 194
41. Shan SQ Rosner GL Braun RD Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma Br J Cancer 76 1997 429 437
42. Mitchell JB Cook JA Krishna MC Radiation sensitisation by nitric oxide releasing agents Br J Cancer 27 1996 S181 S184
43. Mitchell JB Wink DA Degraff W Hypoxic mammalian cell radiosensitisation by nitric oxide Cancer Res 53 1993 5845 5848
44. Arai H Hori S Aramori I Cloning and expression of a cDNA encoding an endothelin receptor Nature 348 1990 730 732
45. Sakurai T Yanagisawa M Takuwa Y Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor Nature 348 1990 627 633
46. Sudjarwo SA Hori T Tanaka Y Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction Biochem Biophys Res Commun 200 1994 627 633
47. Karne S Jayawickreme CK Lerner MR Cloning and characterisation of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores J Biol Chem 268 1993 19126 19133
48. Lüshcer TF Yang Z Tschudi M Interaction between endothelin-1 and endothelium derived relaxing factor in human arteries and veins Circ Res 66 1990 1088 1094
49. Filep JG Foldes-Filep E Rousseau A Vascular responses to endothelin-1 following inhibition of nitric oxide synthase in the conscious rat Br J Pharmacol 110 1993 1213 1221
50. Webb DJ Endogenous endothelin generation maintains vascular tone in humans J Hum Hypertens 9 1995 459 463
51. Boulanger C Luscher TF Release of endothelin from the porcine aorta: Inhibition by endothelin-derived nitric oxide J Clin Invest 85 1990 587 590
52. (suppl) Warner TD Mitchell JA Nucci de G Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of rat and rabbit J Cardiovasc Pharmacol 13 1989 S85 S88
53. Chou S-Y Porush JG Renal actions of endothelin-1 and endothelin-3: Interactions with the prostaglandin system and nitric oxide Am J Kidney Dis 26 1995 116 123
54. Markewitz BA Michael JR Kohan DE Endothelin-1 inhibits the expression of inducible nitric oxide synthase Am J Physiol 276 6Pt 1 1997 1078 1083
55. Burnett JC Coronary endothelial dysfunction in the hypertensive patient: From myocardial ischemia to heart failure J Hum Hypertens 11 1997 45 49
56. Ishibashi M Fujita M Nagai K Production of secretion of endothelin by hepatocellular carcinoma J Clin Endocrinol 76 1993 378 383
57. Nakamuta M Ohashi M Tabata S High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma Am J Gastroendocrinol 88 1993 248 252
58. Nelson JB Hedican SP George DJ Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate Nat Med 1 1995 944 950
59. Kusuhara M Yamaguchi K Nagasaki K Production of endothelin in human cancer cell lines Cancer Res 50 1990 3257 3261
60. Bell KM Prise VE Shaffi KM A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: Influence of tumour size on angiotensin II response Int J Cancer 67 1996 730 738
61. Bell KM Prise VE Chaplin DJ Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumur J Cardiovasc Pharmacol 26 1995 S222 S225
62. Bell KM Prise VE Chaplin DJ Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma Br J Cancer 74 1996 S161 S163
63. Douglas SA Beck JR Elliott JD Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein Br J Pharmacol 114 1995 1529 1540
64. Honess DJ Bleehen NM Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined Br J Cancer 71 1995 1175 1180
65. Robinson SP Rodrigues LM Ojugo ASE The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging Br J Cancer 75 1997 1000 1006
66. Rodrigues LM Maxwell RJ McSheey PMJ In vivo detection of ifosfamide by 31P-MRS in rat tumours: Increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas Br J Cancer 75 1997 62 68
67. Dewhirst MW Ong ET Rosner GL Arteriolar oxygenation in tumour and subcutaneous arterioles: Effects of inspired air oxygen content Br J Cancer 74 1996 S241 S246
68. 2, microcirculatory function and radiosensitivity Int J Radiat Oncol Biol Phys 40 1998 943 951
69. Powell MEB Hill SA Saunders MI Effect of carbogen breathing on tumour microregional blood flow in humans Radiother Oncol 41 1996 225 231
70. Calcutt G Ting SM Preece AW Tissue NAD levels and the response to irradiation on cytotoxic drugs Br J Cancer 24 1970 380 388
71. Chaplin DJ Horsman MR Trotter MJ Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour J Natl Cancer Inst 82 1990 672 676
72. Horsman MR Chaplin DJ Brown JM Tumor radiosensitization by nicotinamide: A result of improved perfusion and oxygenation Radiat Res 118 1989 139 150
73. Horsman MR Chaplin DJ Overgaard J The combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells Cancer Res 50 1990 7430 7436
74. Hill SA Chaplin DJ The effect of nicotinamide on microregional blood flow within tumour assessed using laser Doppler microprobes Acta Oncol 34 1995 401 404
75. Chaplin DJ Horsman MR Aoki DS Nicotinamide, Fluosol DA and carbogen: A strategy to reoxygenate hypoxic cells in vivo: Importance of nicotinamide dose and pre-irradiation breathing time Br J Cancer 68 1991 269 273
76. Kjellen E Joiner MC Collier JM A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments Radiother Oncol 22 1991 81 91
77. Rojas A Joiner MC Denekamp J Extrapolation from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy Radiother Oncol 24 1992 123 124
78. Rojas A Hirst VK Calvert K Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy Int J Radiat Oncol Biol Phys 34 1996 357 365
79. Kaanders JHAM Stratford MRL Liefers J Administration of nicotinamide during a five to seven week course of radiotherapy: Pharmacokinetics, tolerance, and compliance Radiother Oncol 43 1997 67 73
80. (suppl) Saunders MI Dische S Clinical results of hypoxic radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide Br J Cancer 74 1996 S271 S278
81. Denekamp J Fowler JF ARCON—Current status: Summary of workshop on preclinical and clinical studies Acta Oncol 36 1997 517 525
82. Powell MEB Hill SA Saunders MI Human tumor blood flow is enhanced by nicotinamide and carbogen breathing Cancer Res 57 1997 5261 5264
83. Folkman J Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
84. Fan TP Jaggar R Bickell R Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Trends Pharmacol Sci 16 1995 57 66
85. (suppl) Song CW Effect of local hyperthermia on blood flow and microenvironment Cancer Res 44 1984 472S 4730S
86. Vaupel P Kallinowski F Physiological effects of hyperthermia Streffer C Hyperthermia and the Therapy of Malignant Tumours 1987 Springer Verlag Berlin, Germany 71 109
87. Eddy HA Alteration in tumour microvasculature during hyperthermia Radiology 137 1980 515 521
88. Eddy HA Sutherland RM Chromelewski G Tumour microvascular response: Hyperthermia and radiation combination Natl Cancer Inst Monogr 61 1982 225 229
89. Vaupel P Mueller Klieser W Otte J Blood flow, tissue oxygenation and pH distribution in malignant tumours upon localised hyperthermia Strahlentherapie 159 1983 73 81
90. Dewhirst MW Hyperthermia treatment of malignant diseases: Current status and a view toward the future Semin Oncol 24 1997 616 625
91. Pass HI Photodynamic therapy in oncology: Mechanisms and clinical use J Natl Cancer Inst 85 1993 443 456
92. Fisher VH Murphree AL Gomer CJ Clinical and preclinical photodynamic therapy Laser Surg Med 17 1995 2 31
93. Selman SH Kreimer-Birnbaum M Keck RW Correlation of tumour blood flow to tumour regression after hematoporphyrin-derivative (HPD) photodynamic therapy to transplantabe bladder tumours Adv Exp Med Biol 193 1985 93 103
94. Star WM Marijnissen HPA Vanden Berg-Block AE Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphrin derivative photoradiation observed in vivo in sandwich observation chambers Cancer Res 46 1986 2532 2540
95. Bremner JCM Bradley JK Stratford IJ Magnetic resonance spectroscopic studies on ‘real-time’ changes in the RIF-1 tumour metabolism and blood flow during and after photodynamic therapy Br J Cancer 69 1994 1083 1087
96. Carswell EA Old LJ Kassel RL An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA 72 1975 3666 3670
97. Kallinowski F Schaefer C Tyler G In vivo targets of recombinant human tumour necrosis factor α, blood flow, oxygen consumption and growth of isotransplanted rat tumours Br J Cancer 60 1989 555 560
98. Eggermont AM Schraffordt Koops H Klausner JM Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas Semin Oncol 24 1997 547 555
99. Bibby MC Double JA Loadman PM Reduction of tumour blood flow by flavone acetic acid: A possible component to therapy J Natl Cancer Inst 81 1989 216 220
100. Zwi LJ Baguley BC Gavin JB Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid J Natl Cancer Inst U S A 81 1989 1005 1013
101. Hill SA Sampson LE Chaplin DJ Antivascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid Int J Cancer 63 1995 119 123
102. Mahadevan V Malik STA Meager A Role of tumor necrosis factor in flavone acetic acid induced tumor vasculature shutdown Cancer Res 50 1990 5537 5542
103. Ching LM Joseph WR Crosier KE Induction of tumor necrosis factor α messenger RNA in human and murine cells by the flavone acetic acid analogue 5, 6 dimethylxanthenone-4-acetic acid (NSC64088) Cancer Res 54 1994 870 872
104. Kerr DJ Maughan T Newlands E Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal cancer Br J Cancer 60 1989 104 106
105. Maughan TS Ward R Dennis I Tumour concentrations of flavone acetic acid (FAA) in human melanoma: Comparison with mouse data Br J Cancer 66 1992 579 582
106. Ludford RJ Colchicine in the experimental chemotherapy of cancer J Natl Cancer Inst 6 1945 89 101
107. Algire GH Legallais FY Anderson BF Vascular reactions of normal and malignant tissues in vivo: VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas J Natl Cancer Inst 14 1954 879
108. Hill SA Lonergan SJ Denekamp J Vinca alkaloids: Anti-vascular effects in a murine tumour Eur J Cancer 29 1993 1320 1324
109. Hill SA Lonergan SJ Denekamp J The effect of vinca alkaloids on tumor blood flow Vaupel P Oxygen Transport to Tissue XV 1994 Plenum Press New York, NY 417 422
110. (suppl) Chaplin DJ Pettit GR Parkins CS Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents Br J Cancer 74 1996 S86 S88
111. Dark GG Hill SA Prise VE Combretastatin A4: An agent that displays potent and selective toxicity towards tumour vasculature Cancer Res 57 1997 1829 1834
112. Watts ME Woodcock M Arnold S Effects of novel and conventional anti-cancer agents on human endothelial cell permeability: Influence of tumour secreted factors Anticancer Res 147 1997 329 334
113. Burrows FJ Thorpe PE Eradication of large solid tumours in mice with an immunotoxic directed against tumor vasculature Proc Natl Acad Sci USA 90 1993 8996 9000
114. Burrows FJ Derbyshire EJ Tazarri PL Endoglin is an endothelial cell proliferation marker that is upregulated in tumour vasculature Clin Cancer Res 1 1995 1623 1634
115. Brooks PC Montgomery AM Rosenfeld M Integrin α v β 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
116. Dvorak HF Sioussat TM Brown LF Distribution of vascular permeability factor (vascular endothelial growth factor) in tumours: Concentration in tumor blood vessels J Exp Med 174 1991 1275 1278
117. Derbyshire EJ Thorpe PE Targeting the tumour endothelium using specific antibodies Bicknell R Lewis CE Ferrara N Tumour Angiogenesis 1997 Oxford University Press Oxford 343 356
118. Kaipainen A Vlaykova T Hatva E Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium metastatic melanoma Cancer Res 54 1994 6571 6577
119. Ozaki K Yoshida T Ide H Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cell, HUVEC Hum Gene Ther 7 1996 1483 1490
120. Pasqualini R Koivunen E Ruoslahti E αv integrins as receptors for tumour targeting by circulating ligands Nat Biotech 15 1997 542 546
121. Woglum WH A critique of tumor resistance J Cancer Res 7 1923 283 311